

# PROGRAM

## WEDNESDAY 24<sup>TH</sup> JUNE

### **Psycho-Oncology Workshop**

1:00pm - 3:30pm

Meeting Room 1 & 2

### **Early Career Research Symposium**

1:00pm - 5:00pm

Meeting Room 3

### **ANZCHOG Executive Council Meeting**

1:00pm - 5:00pm

Conference Room 5

### **Afternoon Tea**

3:30am - 4:00pm

Exhibition Area

### **Psycho-Oncology Group Meeting**

4:00pm - 5:30pm

Meeting Room 1 & 2

# THURSDAY 23<sup>RD</sup> JUNE

## JOINT ANR/ANZCHOG DAY

### **ANZCHOG Welcome**

9:00am - 9:10am

Hall A

### **Plenary Session 4**

9:10am - 10:30am

Hall A

Chairs: Gudrun Schleiermacher & Sue Cohn

9:10 AM **Julie R Park**

A Phase 3 randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study *abs# 90*

9:26 AM **Rajen Mody**

Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group (COG) *abs# 91*

9:42 AM **Mark A Applebaum**

Second malignancies in patients with neuroblastoma: a report from the international neuroblastoma risk group project *abs# 92*

9:58 AM **Ulrike Pötschger**

The way towards an international mIBG skeletal score for high risk neuroblastoma: the statistical perspective *abs# 93*

10:14 AM **Ruth Ladenstein**

Final results of the randomised short term infusion (STI) of ch14.18/CHOmAB immunotherapy in combination with Aldesleukin: a report on outcome and toxicities from the HR-NBL1/SIOPEN trial *abs# 94*

### **Morning Tea**

10:30am - 11:00am

Exhibition Area

### **Parallel 11 Biomarkers and Novel Approaches**

11:00am - 12:30pm

Meeting room 1 & 2

Chairs: Per Kogner & Pat Reynolds

- 11:00 AM **Iedan Verly**  
Catecholamine metabolites: novel diagnostic insight, correlations with biological features and prediction of clinical outcome in patients with neuroblastoma *abs# 95*
- 11:15 AM **Anne Hakkert**  
High frequency of Cytosine to Adenine mutations in neuroblastoma correlates with genomic aberrations in 8-Oxo-Guanine repair pathway *abs# 96*
- 11:30 AM **Geertrui Denecker**  
The FOXM1 target gene BIRC5 (survivin) is a top ranked dosage sensitive gene located on the common large copy number 17q gained segment in neuroblastoma. *abs# 97*
- 11:45 AM **Belamy B Cheung**  
Identification of novel small molecule compounds to restore sensitivity to trophic factor withdrawal in MYCN-initiated death resistant cells *abs# 98*
- 12:00 PM **Fikret Rifatbegovic**  
Metronomic Topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells *in vitro* and *in vivo* by therapy induced senescence *abs# 99*
- 12:15 PM **Michael M Song**  
High MYCN, low MYC, low CERS4, and low anti-apoptotic BCL2 gene family expression are associated with sensitivity to fenretinide in neuroblastoma cell lines and PDXs *abs# 100*

### **Parallel 12 Immunotherapy and Early Phase Trials**

11:00am - 12:30pm

Meeting room 3 & 4

Chairs: Daniel Morgenstern & Rajen Mody

- 11:00 AM **Annette Kuenkele**  
Preclinical assessment of CD171-directed CAR T cell adoptive

therapy for childhood neuroblastoma: CE7 epitope target  
safety and product manufacturing feasibility *abs# 101*

- 11:15 AM **Holger N Lode**  
Phase II clinical trial with long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHO in combination with interleukin-2 (IL2) showed clinical efficacy and improved toxicity in patients with high risk neuroblastoma. *abs# 102*
- 11:30 AM **Sara M. Federico**  
Humanized anti-gd2 antibody (hu14.18k322a) with Chemotherapy +/- parental natural killer (nk) cells in children with recurrent/ refractory Neuroblastoma *abs# 103*
- 11:45 AM **Shahab Asgharzadeh**  
Tumor-associated macrophage polarization state and the dynamic nature of PDL1 expression in neuroblastomas *abs# 104*
- 12:00 PM **Julie R Park**  
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A phase 1 study of autologous T-cells lentivirally transduced to express CD171-specific Chimeric Antigen Receptors (CAR) for recurrent/refractory high-risk neuroblastoma (HR-NB) *abs# 105*
- 12:15 PM **Steven G. DuBois**  
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium *abs# 106*

## **Neuroblastoma Update - 1**

11:00am - 12:30pm

Hall A

Chairs: Sue Cohn & Andy Pearson

- 11:00 AM **Sharon Diskin**  
Overview of neuroblastoma epidemiology and genetic predisposition *abs# 107*

- 11:20 AM **Frank Speleman**  
Actionable genomic mutations *abs# 108*
- 11:40 AM **Susan Cohn**  
Updates on the International Neuroblastoma Risk Group (INRG). Classification System and Interactive INRG Database (iINRGdb) *abs# 109*
- 12:00 PM **Gudrun Schleiermacher**  
Overview of treatment for low- and intermediate-risk patients *abs# 110*

### **Lunch**

12:30pm - 1:30pm Exhibition Area

### **Industry sponsored workshop: United Therapeutics**

12:45pm - 1:25pm Meeting room 3 & 4

### **Parallel 13 - Genome Wide Analysis and Genetic Variation**

1:30pm - 3:30pm Meeting room 3 & 4

Chairs: Frank Westermann & Katleen De Preter

- 1:30 PM **Mario Capasso**  
Whole exome and deep targeted sequencing of clinically aggressive neuroblastomas reveal recurrent somatic mutations in pathways involved in cancer progression *abs# 111*
- 1:45 PM **Sharon J. Diskin**  
Identification of germline mutations in 776 children with neuroblastoma *abs# 112*
- 2:00 PM **Fakhra Ikram**  
Fusion-transcripts are associated with an unfavourable phenotype in neuroblastoma *abs# 113*
- 2:15 PM **Paul Deveau**  
Clonal reconstruction in neuroblastoma shows enrichment of mutations in cell survival and DNA-repair pathways at relapse *abs# 114*
- 2:30 PM **Frank Westermann**  
Chromosomal rearrangements juxtapose active enhancer elements to oncogenes in high-risk neuroblastoma *abs# 115*

2:45 PM **Carolina Rosswog**  
Molecular risk assessment of neuroblastoma patients  
eliminates the necessity of clinical prognostic markers  
*abs# 116*

3:00 PM **Mark A Applebaum**  
Genetic variants in *BARD1* and *KIF15* are associated  
with *MYCN*-amplification in neuroblastoma  
*abs# 117*

3:15 PM **Navin Pinto**  
Pharmacogenetics of treatment response in patients with  
high-risk neuroblastoma, a Children's Oncology Group study  
*abs# 118*

#### **Parallel 14 Clinical Awards Session**

1:30pm - 3:30pm

Meeting room 1 & 2

Chairs: Holger Lode & Jed Nuchtern

1:30 PM **Lucas Moreno**  
Predicting "early" relapse/progression/death in children with  
INRGSS Stage M neuroblastoma using clinical and biologic  
factors: An INRG database analysis  
*abs# 119*

1:45 PM **Meredith S Irwin**  
Revised Children's Oncology Group (COG) risk stratification  
incorporating the international neuroblastoma risk group  
staging system  
*abs# 120*

2:00 PM **Ji Won Lee**  
High-dose <sup>131</sup>I-MIBG treatment incorporated into tandem  
HDCT/auto-SCT for high-risk neuroblastoma: Results of SMC  
NB-2009 study  
*abs# 121*

2:15 PM **Kelly Huibregtse**  
Incidence and risk factors for secondary malignancy in  
patients with neuroblastoma after treatment with <sup>131</sup>I-  
metaiodobenzylguanidine  
*abs# 122*

2:30 PM **Pablo Berlanga**  
Central nervous system relapses in patients with high-risk  
neuroblastoma: the SIOPEN experience  
*abs# 123*

2:45 PM **Andras Heczey**  
Autologous T cells expressing a GD2 specific chimeric

antigen receptor with CD28 and OX40 costimulatory  
endodomains for children with neuroblastoma *abs# 124*

3:00 PM

**Holger N Lode**

Killer-cell Ig-like receptor (KIR) haplotypes and Fc $\gamma$ -receptor polymorphisms correlate with antibody-dependent cell-mediated cytotoxicity levels and survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHO in combination with interleukin-2 (IL-2) *abs# 125*

3:15 PM

**Araz Marachelian**

A Phase I Study of Lenalidomide in Combination with ch14.18 and isotretinoin in Patients with Refractory/Recurrent Neuroblastoma (RR-NB): New Approaches to Neuroblastoma Therapy (NANT) Consortium Trial *abs# 126*

## **Neuroblastoma Update - 2**

1:30pm - 3:30pm

Hall A

Chairs: Sue Cohn & Andy Pearson

1:30 PM

**Julie Park**

Overview of treatment for high-risk patients

*abs# 127*

2:00 PM

**Lucas Moreno**

Overview of treatment for relapsed disease

*abs# 128*

2:30 PM

**Lisa Diller**

Long-term effect of treatment

*abs# 129*

## **Afternoon Tea**

3:30pm - 4:00pm

Exhibition Area

## **Keynote 4**

4:00pm - 4:45pm

Hall A

Chair: Julie Park

4:00 PM

**Stephan Grupp**

Not available at time of print

*abs# 130*

## **ANR Closing Ceremony**

4:45pm - 5:15pm

Hall A

Chair: Michelle Haber

## **Conference Dinner**

7:00pm - 10:00pm

Hall 2



## FRIDAY 24<sup>TH</sup> JUNE

### **Plenary 1**

9:00am - 10:30am

Meeting room 3 & 4

Chair: Andrew Moore and Chris Fraser

Session Sponsored by:



9:00 AM **Joanne Aitken**

Australian Paediatric Cancer Registry Update

abs# 1

9:45 AM **Hamish Scott**

"Bond. James Bond." Familial Leukaemia and lymphoma, the next generation- redefining familial haematological risk through the Australian Familial Haematological Cancer Study abs# 2

### **Morning Tea**

10:30am - 11:00am

Mezzanine Level Foyer

### **Plenary 2**

11:00am - 12:30pm

Meeting room 3 & 4

Chair: Andrew Moore

11:00 AM **Glenn Marshall**

Zero Childhood Cancer Program

abs# 3

11:30 AM **Deborah White**

Personalised Medicine for High Risk ALL

abs# 4

12:00 PM **Julia Clark**

Invasive Viral Infections in Haematopoietic Stem Cell Transplant Patients

abs# 5

### **Lunch**

12:30pm - 1:30pm

Mezzanine Level Foyer

### **ANZCHOG AGM (ANZCHOG members only)**

12:30pm - 1:30pm

Meeting room 3 & 4

Chair: Chris Fraser

### **Plenary 3 - Collaborative care in Oceania and the Pacific Rim**

1:30pm - 2:40pm

Meeting room 3 & 4

Chair: Ross Pinkerton

Session sponsored by:



- 1:30 PM **Jane Skeen**  
The New Zealand Scene *abs# 6*
- 1:45 PM **Helen Irving**  
Overview of innovations in shared care in Australia and this Region *abs# 7*
- 1:55 PM **Debbie Young**  
Return to Country *abs# 8*
- 2:10 PM **Joanne Aitken**  
International Data Consistency *abs# 9*
- 2:20 PM **Discussion & ANZCHOG's Role**

### **Rapid Fire - Poster presentations**

2:40pm - 3:05pm

Meeting room 3 & 4

Facilitator: Andrew Moore

- 2:40 PM **Penelope J Slater**  
Telling the story of childhood cancer – an evaluation of the Discovery Interview methodology within the Queensland Paediatric Palliative Care, Haematology and Oncology Network *abs# 131*
- 2:43 PM **Natalie Koopmans**  
Comparison of usual nutrition service delivery with a risk-adapted service model for newly diagnosed paediatric oncology patients- a pilot study *abs# 132*
- 2:46 PM **Julia Leigh**  
By My Side: The development of unique bereavement resource for parents who have experienced the death of a child from cancer *abs# 133*
- 2:49 PM **Stephanie Arrott-Watt**  
The AYA Clinic: It's what they wanted *abs# 134*

- 2:52 PM **Julia Clark**  
Exploring the Epidemiology and Risk Factors for Invasive Fungal Infections (IFI's) In Immunocompromised Children (TERIFIC) *abs# 136*
- 2:55 PM **Kate Turpin**  
A Statewide approach to survivorship care in South Australia (SA): from paediatrics to adults *abs# 137*
- 2:58 PM **Eden Robertson**  
Health literacy in adolescents and young adults: Implications for the delivery of AYA-oncology friendly care *abs# 138*

**Afternoon Tea & Poster Viewing**

3:05pm - 3:30pm Mezzanine Level Foyer

**Parallel: ACCT Trials & Research Update**

3:30pm - 5:00pm Meeting room 3 & 4

Chair: Geoff McCowage

3:30 PM **Geoffrey McCowage**  
ACCT Update *abs# 10*

4:30 PM **Andrew Moore**  
Networking Childhood Cancer Biobanking in Australia and New Zealand

**Parallel: Dr Paul Gibney**

3:30pm - 5:00pm Meeting Room 5

3:30 PM **Paul Gibney**  
The application of family therapy principles in an acute health care crisis *abs# 11*

**Mixer Function**

5:00pm - 9:00pm Mezzanine Level Foyer

**SATURDAY 25<sup>TH</sup> JUNE**

**ANZCHOG Nursing Group - Open Meeting**

8:00am - 9:00am Meeting room 3 & 4

**Parallel: Oral Abstracts 1**

9:00am - 10:30am

Meeting room 3 & 4

Chair: Helen Irving

9:00 AM **Richard Martin**

Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Pediatric Hematopoietic Stem Cell Transplantation (HSCT): Subanalysis Data from an Open-Label, Phase III, Randomized Trial *abs# 12*

9:15 AM **Christine L White**

Targeting STAT3 protects males from Sonic Hedgehog Medulloblastoma *abs# 13*

9:30 AM **Shiqi (Stacie) Wang**

A review of the clinical impact of FDG-PET/CT on the management of paediatric oncology patients with prolonged or recurrent fever. *abs# 14*

9:45 AM **Richard Mitchell**

TCR  $\alpha^+ \beta^+$ /CD19<sup>+</sup> cell depleted haploidentical haematopoietic stem cell transplantation for paediatric patients *abs# 15*

10:00 AM **Dean Popovski**

Pharmacological inhibition of EZH2 synergises with low-dose HDACi in Malignant Rhabdoid Tumours. *abs# 16*

10:15 AM **Claire E Wakefield**

Genetic testing for childhood cancer survivors' risk of late effects: Consumer understanding, acceptance and willingness-to-pay *abs# 17*

**Parallel: Oral Abstracts 2**

9:00am - 10:30am

Meeting Room 5

Chair: Rachel Edwards

- 9:00 AM **Joanna E Fardell**  
Long-term childhood cancer survivors' and parents' information needs: implications for survivorship models of care *abs# 18*
- 9:15 AM **Belinda Matigian**  
'We've Run Out of Options' – Transitioning Adolescents into Palliative Care: A Case Study Perspective *abs# 19*
- 9:30 AM **Philippa E Fielden**  
the oncology family app, providing families with cancer care information at their fingertips *abs# 20*
- 9:45 AM **Mary A Burns**  
Advance care planning for adolescents and young adults with cancer: A multi-perspective evaluation of *Voicing my Choices™* *abs# 21*
- 10:00 AM **Angela Delaney**  
Music therapy & paediatric palliative care: translating research into clinical practice to improve the effect of music therapy on perceived pain for children with life-limiting illness and their families. *abs# 22*
- 10:15 AM **Joanna E Fardell**  
Outcomes of bereaved parents whose child did or did not participate in an early phase clinical trial *abs# 23*

**Morning Tea**

10:30am - 11:00am

Mezzanine Level Foyer

**Plenary 4 - Oncofertility Symposium**

11:00am - 12:30pm

Meeting room 3 & 4

Chair: Romi DasGupta and Maria McCarthy

- 11:00 AM **Peter Downie**  
Cancer and Fertility abs# 24
- 11:15 AM **Yasmin Jayasinghe**  
Fertility Preservation – the past, present, and future abs# 25
- 11:35 AM **Rosalind McDougall**  
An ethical framework for fertility preservation in children  
abs# 26
- 11:50 AM **Sonia Read**  
Legal Challenges abs# 27
- 12:10 PM **Panel Discussion**

**Presentations of Awards and Meeting Close**

12:30pm - 12:40pm

Meeting room 3 & 4

Awards sponsored by



**Pharmacy Group Meeting (closed meeting)**

1:00pm - 3:00pm

Meeting room 3 & 4

**Nursing Group – Research Meeting (closed meeting)**

1:00pm - 3:00pm

Meeting Room 5